Stellate Ganglion Block for Chronic Fatigue Syndrome

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Neuroversion, Anchorage, AKChronic Fatigue Syndrome+7 MoreBupivacaine Injection - Drug
Eligibility
18 - 50
Female
What conditions do you have?
Select

Study Summary

This trial will investigate if SGB can improve symptoms in people with ME/CFS, and if so, what changes in the body accompany those improvements.

Eligible Conditions
  • Chronic Fatigue Syndrome (CFS)
  • Chronic Fatigue Syndrome
  • Myalgic Encephalomyelitis (ME)
  • Chronic Infectious Mononucleosis-Like Syndrome

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 4 Secondary · Reporting Duration: 2 months

2 months
Change in Autonomic Tone at 2 Months
Change in Cognitive Function at 2 Months
Change in Metabolites at 2 Months
Change in Orthostatic Tolerance at 2 Months
Change in Salivary Cortisol Upon Awakening at 2 Months
Change in Subjective Rating of Symptoms at 2 Months
2 weeks
Change in Autonomic Tone at 2 Weeks
Change in Cognitive Function at 2 Weeks
Change in Metabolites at 2 Weeks
Change in Orthostatic Tolerance at 2 Weeks
Change in Salivary Cortisol upon Awakening at 2 Weeks
Change in Subjective Rating of Symptoms at 2 Weeks

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Stellate Ganglion Block
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Stellate Ganglion Block · No Placebo Group · Phase 1

Stellate Ganglion Block
Drug
Experimental Group · 1 Intervention: Bupivacaine Injection · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupivacaine Injection
2017
Completed Phase 4
~320

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 months

Who is running the clinical trial?

Neuroversion, Inc.Lead Sponsor
Deborah L Duricka, PhDPrincipal InvestigatorNeuroversion, Inc.

Eligibility Criteria

Age 18 - 50 · Female Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Your body mass index (BMI) falls between 18 and 29 kilograms per square meter.
You are a woman.
If you have been diagnosed with ME/CFS (using CCC and IOM criteria), you must have had the condition for at least 4 years before enrolling in the study.
References

Frequently Asked Questions

Is this research protocol accepting participants aged 30 and up?

"This trial is open to adults between the ages of 18 and 50." - Anonymous Online Contributor

Unverified Answer

To what extent might Stellate Ganglion Block endanger patients?

"Taking into consideration the limited evidence available, Stellate Ganglion Block has been assessed by our team at Power to be of low risk and granted a score of 1." - Anonymous Online Contributor

Unverified Answer

Are new volunteers being accepted for this scientific experiment?

"Presently, this clinical trial is not actively seeking patients. The study was initiated on 1/1/2023 and last updated on 12/21/2022 according to the details posted on clinicaltrials.gov. Nonetheless, there are over 1800 other studies currently in search of volunteer participants." - Anonymous Online Contributor

Unverified Answer

What are the ultimate goals of this experiment?

"The primary aim of this two-week clinical trial is to analyse the Changes in Subjective Rating of Symptoms at 2 Months. Secondary objectives include gauging changes in Orthostatic Tolerance, Autonomic Tone, and Blood Oxidation both after a fortnight and once two months have passed since treatment began. To measure these metrics accurately, The 10-minute National Aeronautics and Space Administration (NASA) lean test will be used for orthostatic tolerance while wearables such as rings worn on fingers paired with smartphones apps are employed for autonomic tone measurements over both time frames." - Anonymous Online Contributor

Unverified Answer

Might I be eligible to participate in this trial?

"A total of 10 individuals between the ages 18 and 50, who have been diagnosed with chronic fatigue syndrome by both CCC and IOM criteria in less than three years prior to enrollment are eligible for this trial. Additionally, those admitted must demonstrate evidence of a viral illness preceeding their ME/CFS diagnosis (e.g., SARS-CoV-2, Epstein-Barr or Influenza), possess a BMI ranging from 18 - 29 kg/m^2 and be able to comprehend English language proficiently." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.